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Nano-liquid chromatography-mass spectrometry (nanoLC-MS) is a powerful tool for a
variety of applications in (bio)analytical chemistry. Combining the use of columns with
reduced inner diameter and the use of column switching systems allows measurements
with increased sensitivity. However, a major challenge in the implementation of such
setups is clogging of columns and connections, which requires labour intensive sample
preparation (1) or the use of high dilution factors (2) to obtain clean extracts.
In order to avoid system clogging and the need for extra, time-consuming offline clean-
up steps, online automatic filtration and filter back-flush (AFFL) was introduced by
Svendsen et al. (3). It has been demonstrated that placing a filter‐union upstream
relative to the trapping cartridge and analytical column greatly reduced backpressure
buildup and did not affect chromatographic performance during the analysis of protein
precipitated plasma samples.
The focus of this current study was to assess the ruggedness of this technique in routine
doping control analysis. As a first application, the hyphenation of dilute-and-shoot
sample clean-up with online AFFL-nanoLC-MS was investigated for the analysis of small
peptide hormones (MW < 2 kDa). The evaluation of ruggedness was based on pressure
monitoring both over the trapping cartridge and the analytical column during ~ 300
injections of diluted urine samples. The practical potential in routine doping control
analysis was shown by evaluating the obtained data based on the World Anti-Doping
Agency (WADA) proposed minimum required performance level (MRPL), and
chromatographic / mass spectrometric identification criteria (TD2015IDCR) (4-5).
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Sample preparation (final conditions): To 125 µL of urine (n=10) (spiked with
peptides (Table 2) at 2 ng/mL), 122.5 µL dilution mix ( 98% H2O, 2% HOAC, 1 ppm
bovine insulin) and 2.5 µL ISTD (100 ng/mL) were added and centrifuged. From the
supernatant, 25 µL was added to an LC-MS vial containing 175 µL dilution mix.
Instrumental analysis: For chromatographic separation, a nano-flow liquid
chromatography system equipped with a high pressure gradient nano-flow pump and a
low pressure gradient micro-flow loading pump was used (Dionex UltiMate 3000
RSLCnano). A PepMap100 C8 trapping column (5 µm, 300 µm x 5 mm) and a PepMap
RSLC C18 analytical column (5 µm, 300 Å, 75 µm x 15 cm, thermostated at 35 °C)
from Thermo Fischer Scientific were used for the preconcentration and separation of
the peptides. The samples were filtrated online through a 1 µm stainless steel filter /
screen (Valco). The schematic view of the switching valve is shown in Figure 1.
Figure 1
The loading mobile phase consisted of: A: 98 % H2O, 2 % ACN, 0.05 % TFA; B: 90 %
ACN, 10 % H2O. The mobile phase delivered by the nano pump consisted of A: 98.8 %
H2O, 1 % DMSO, 0.2 % HCOOH; B: 80 % ACN, 18.8 % H2O, 1 % DMSO, 0.2 %
HCOOH. The injection volume was 6 µL. The applied gradients and programming of
the positions of the 10 port switching valve are demonstrated in Table 1.
Table 1
The LC-system was coupled with a Q-Exactive Plus mass spectrometer, equipped with
a Thermo Scientific™ EASY-Spray™ electrospray ionization source. The parameters
of the ion source were: spray voltage 1.7 kV, capillary temperature 300 °C, S-lens 70.
The instrument was set to operate in full scan (FS) and in parallel reaction monitoring
(PRM) mode. The settings were resolution 35000 (at m/z 200), AGC target 1e5,
maximum ion injection time 110 ms, isolation width 2.2 m/z, loop count 8 and
resolution 70000 (at m/z 200), AGC 1e6, injection time 200 ms for the PRM and for the
FS modes, respectively. The selected, characterized ions (precursor / product ions)
and applied collision energies are listed in Table 2. Mass extraction width was 5 ppm.
In this study, AFFL-nanoLC-MS was tested in a routine doping control setting. No
pressure increase was observed either over the trapping or the analytical column in the
course of this ongoing study, and both the MRPL and identification criteria were met for
all peptides at the investigated concentration level. The future plans include a full
validation of the method for the confirmatory analysis of small peptides, and further
testing of the ruggedness of the setup by the injection of different matrices, subjected to
different sample clean-up procedures.
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Lys(8)-Vasopressin 528.7230 (+2) 226.1550 (b8-b6) 300.2030 (y3) 25
Arg(8)-Vasopressin 542.7262 (+2) 276.1343 (b4-b2) 328.2092 (y3) 20
(deamino Cys1, Val 4, D-
Arg8) AVP
ISTD 1
1040.4441 (+1) 399.1373 (b3) 311.1826 (y3-NH3) 35
Desmopressin 1069.4342 (+1) 276.1343 (b4-b2) 311.1826 (y3-NH3) 35
Terlipressin 614.2552 (+2) 203.1503 (y2) 300.2030 (y3) 25
Felypressin 520.7257 (+2) 203.1503 (y2) 300.2030 (y3) 25













Peforelin 420.5283 (+3) 249.0982 (b2) 172.1081 (y2) 25
LHRH 591.7914 (+2) 435.1775 (b3) 172.1081 (y2) 20
LHRH_(2-10) 536.2778 (+2) 934.4894 (y8) 748.4101 (y7) 25
LHRH_(1-3)OH 453.1881 (+1) 221.1033 (a2) 249.0982 (b2) 30
Leuprolide 605.3300 (+2) 221.1033 (a2) 249.0982 (b2) 30
Leuprolide_(1-3)OH 453.1881 (+1) 221.1033 (a2) 249.0982 (b2) 30
Leuprolide_(5-9) 344.7289 (+2) 249.1598 (a2) 412.3031 (y3) 10
Goserelin 635.3285 (+2) 221.1033 (a2) 249.0982 (b2) 25
Lecirelin 605.3300 (+2) 221.1033 (a2) 249.0982 (b2) 30
Triptorelin 656.3227 (+2) 249.0982 (b2) 328.2092 (y3) 20
Buserelin 620.3353 (+2) 221.1033 (a2) 249.0982 (b2) 25
Deslorelin 641.8276 (+2) 249.0982 (b2) 299.2190 (y2) 25
Nafarelin 661.8251 (+2) 249.0982 (b2) 328.2092 (y3) 20
Nafarelin_(5-10) 401.2245 (+2) 333.1598 (a2) 441.2932 (y4) 15






Alexamorelin 479.7560 (+2) 181.1084 (a2) 209.1030 (b2) 40
GHRP-1 478.2505 (+2) 181.1084 (a2) 209.1039 (b2) 40
GHRP-1_(2-4)OH 424.1979 (+1) 307.1548 (a2) 335.1493 (b2) 25
GHRP-1_(3-7) 374.20248 (+2) 241.1335 (a2) 269.1285 (b2) 10
GHRP-2 409.7210 (+2) 170.0964 (a1) 241.1335 (a2) 30
GHRP-2_(1-3)OH 358.17613 (+1) 198.0913 (b2-b1) 287.1390 (y2) 15
13C, 15N GHRP-2_(1-3)OH
ISTD 2
362.1820 (+1) 170.0964 (a1) 241.1335 (a2) 25
GHRP-3 328.2056 (+1) 272.1394 (b2) 384.2718 (y3) 10
GHRP-4 608.2979 (+1) 444.2038 (b3) 351.1816 (y2) 20
GHRP-5 771.3613 (+1) 421.1870 (b3) 334.1550 (z2) 25
GHRP-6 437.2296 (+2) 129.1022 (Lys der.) 324.1455 (b2) 25
GHRP-6_OH 437.72157 (+2) 395.1826 (b3) 324.1455 (b2) 25
GHRP-6_(2-6) 368.7001 (+2) 230.1288 (a2) 479.2765 (y3) 15
GHRP-6_(2-6)OH 369.1926 (+2) 258.1237 (b2) 294.1812 (y2) 25
GHRP-6_(2-5)OH 609.28237 (+1) 352.1656 (y2) 335.1390 (z2) 20
Hexarelin 444.2374 (+2) 129.1022 (Lys der.) 110.0713 (His-imm.) 20
Hexarelin_(4-6) 479.2765 (+1) 306.1601 (a2) 146.1288 (y1) 25
Hexarelin_(1-3)OH 427.2088 (+1) 310.1662 (a2) 338.1612 (b2) 25
Hexarelin_(2-5)OH 623.2981 (+1) 352.1656 (y2) 335.1390 (z2) 20













Ibutamoren 529.2470 (+1) 263.1390 267.1162 20
Tabimorelin 529.3173 (+1) 280.1332 252.1383 30
Anamorelin 547.3391 (+1) 174.1277 276.2076 40
Capromorelin 506.2762 (+1) 263.1390 244.1444 18
Ipamorelin 356.7001 (+2) 129.1022 (Lys der.) 223.1195 (b2) 40

















TB-500 445.2531 (+2) 248.1241 (y2) 606.3093 (y5) 25









ts AOD-9604 605.6274 (+3) 136.0757 (Tyr-Imm.) 223.1077 (y2) 20
AOD-9604_(7-16) 521.7077 (+1) 820.3076 (b8) 877.3291 (b9) 20
Table 2
Figure 2
The ruggedness of the method was tested by continuous pressure monitoring over the
trapping and the analytical column (Figure 2). No backpressure increase (related to
clogging) was observed, even when two-fold diluted urine samples were injected.
However, several parameters, including the dilution factor had to be optimized to be
compliant with the TDICR2015 (5).
